Posts

MV140 enhances the response to Candida albicans

{$excerpt:n}

.

01/2021. Candida albicans in combination with MV140

An interesting study on the immunomodulatory effect of MV140 (Uromune) in combination with Candida albicans has been published in Frontiers in Immunology.   

MV140 (Uromune) is a sublingual vaccine manufactured by INMUNOTEK composed of inactivated bacteria, designed to prevent recurrent urinary tract infections. Candida albicans is a fungus that causes recurrent infections of the vulva and vagina. Recurrent vulvo-vaginitis is frequently associated with urinary tract infections.

In this study, the effect of combining MV140 with Candida albicans (V132) on the function of cells that are essential in the immune response against this pathogen is experimentally analyzed. The results of this research indicate that the MV140/V132 combination enhances responses with potential to confer resistance against infection by this fungus, while inducing others that limit excess inflammation.

The study also shows that the MV140/V132 combination can be adscribed to the new concept of trained immunity-based vaccines (TIbVs).

This research has been carried out in the Department of Biochemistry and Molecular Biology, Faculty of Chemistry, Complutense University of Madrid, under the direction of Prof. Oscar Palomares, with the collaboration of the Department of Immunology, Hospital Clínico San Carlos (Madrid) and INMUNOTEK.

La entrada MV140 enhances the response to Candida albicans se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK listed in CEPYME500 of 2020

{$excerpt:n}

12/2020. INMUNOTEK listed in CEPYME500 of 2020

INMUNOTEK listed again in CEPYME500.

This is an initiative of CEPYME (State Confederation of Small and Medium-sized Enterprises) to identify, select and promote the 500 companies that lead business growth, both in terms of their results and their capacity to generate added value, employment, innovation and international projection.

INMUNOTEK entered this ranking in its first edition (2017) and has been selected again in this year’s edition.

As stated in CEPYME500, the main function of this initiative is to grant national and international recognition and projection to selected companies.


La entrada INMUNOTEK listed in CEPYME500 of 2020 se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK listed in CEPYME500 2020

{$excerpt:n}

12/2020. INMUNOTEK listed in CEPYME500

INMUNOTEK has been chosen to enter in CEPYME500.

This is an initiative of CEPYME (State Confederation of Small and Medium-sized Enterprises) to identify, select and promote the 500 companies that lead business growth, both in terms of their results and their capacity to generate added value, employment, innovation and international projection.

INMUNOTEK already entered this ranking in 2017 and has been selected again in this year’s edition. 

As stated in CEPYME500, the main function of this initiative is to grant national and international recognition and projection to selected companies.


La entrada INMUNOTEK listed in CEPYME500 2020 se publicó primero en Inmunotek.


Source: Inmunotek News

European patent granted

{$excerpt:n}

12/2020. European patent granted

The European Patent Office (EPO) has granted the patent EP2982381B1 “Immunogenic complex for vaccination and method for the production thereof” requested by INMUNOTEK.

The invention relates to hypoallergenic polymerized neoglycoconjugates (allergoids-mannan) developed for the design of new anti-allergy vaccines trageting dendritic cells. This patent joins those already granted by Japan, US, Mexico and China for these immunogenic complex.

Allergoids can be coupled to mannan improving their bioavailability for allergy immunotherapy and producing positive immunomodulatory effects. The invention is the result of an INMUNOTEK research project that has received funding from the Center for Industrial Technological Development (MINECO, Spain) and the collaboration of researchers from the CIB-CSIC and Complutense University (Madrid). These vaccines are currently in the clinical development stage.


Bibliography:

Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. Manzano AI, Javier Cañada F, Cases B, Sirvent S, Soria I, Palomares O, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Subiza JL. Glycoconj J. 2016 Feb;33(1):93-101. doi: 10.1007/s10719-015-9640-4. Epub 2015 Nov 25.

Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. Sirvent S, Soria I, Cirauqui C, Cases B, Manzano AI, Diez-Rivero CM, Reche PA, López-Relaño J, Martínez-Naves E, Cañada FJ, Jiménez-Barbero J, Subiza J, Casanovas M, Fernández-Caldas E, Subiza JL, Palomares O. J Allergy Clin Immunol. 2016 Aug;138(2):558-567.e11. doi: 10.1016/j.jaci.2016.02.029. Epub 2016 Apr 13

Dendritic cell targeting with C-type lectins for improvement of allergen immunotherapy. Schülke S, Vieths S. J Allergy Clin Immunol. 2016 Aug;138(2):568-70. doi: 10.1016/j.jaci.2016.06.006. Epub 2016 Jun 23.

Human basophils may not undergo modulation by DC-SIGN and mannose receptor–targeting immunotherapies due to absence of receptors. Das M, Galeotti C, Stephen-Victor E, Karnam A, Kaveri SV, Bayry J. J Allergy Clin Immunol. 2017 Apr;139(4):1403-1404.e1. doi: 10.1016/j.jaci.2016.09.062. Epub 2017 Jan 11.

Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. Soria I, Alvarez J, Manzano AI, López-Relaño J, Cases B, Mas-Fontao A, Cañada FJ, Fernández-Caldas E, Casanovas M, Jiménez-Barbero J, Palomares O, Viñals-Flórez LM, Subiza JL. Vet Immunol Immunopathol. 2017 Aug;190:65-72. doi: 10.1016/j.vetimm.2017.07.004. Epub 2017 Jul 23.

Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. Soria I, López-Relaño J, Viñuela M, Tudela JI, Angelina A, Benito-Villalvilla C, Díez-Rivero CM, Cases B, Manzano AI, Fernández-Caldas E, Casanovas M, Palomares O, Subiza JL. Allergy. 2018 Apr;73(4):875-884. doi: 10.1111/all.13396. Epub 2018 Jan 31.

Novel vaccines targeting dendritic cells by coupling allergoids to mannan. Benito-Villalvilla, C., Soria, I., Subiza, J.L. et al. Allergo J Int (2018). https://doi.org/10.1007/s40629-018-0069-8

A pilot study of immunotherapy in dogs with atopic dermatitis using a mannan‐Dermatophagoides farinae allergoid targeting dendritic cells. González, J.‐L., Zalve, V., Fernández‐Caldas, E., Cases, B., Subiza, J.‐L. and Casanovas, M. (2018) Vet Dermatol, 29: 449-e152. https://doi.org/10.1111/vde.12679

Alum impairs tolerogenic properties induced by allergoid‐mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs. Benito‐Villalvilla, C, Soria, I, Pérez‐Diego, M, Fernández‐Caldas, E, Subiza, JL, Palomares, O. (2019) Allergy. 75: 648– 659. https://doi.org/10.1111/all.14036


La entrada European patent granted se publicó primero en Inmunotek.


Source: Inmunotek News

CIEGE Seal for INMUNOTEK at Business Excellence

{$excerpt:n}

11/2020. INMUNOTEK revalidates the CIEGE Seal

INMUNOTEK obtains the CIEGE Seal for excellence in business management for the second consecutive year

Obtaining the CIEGE Seal (Informa-elEconomista Excellent Management Certificate) requires exceeding 57 indicators from 10 different categories (solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization).

CIEGE Seal is an initiative of Informa D&B (a subsidiary of CESCE), a leader in providing Financial Information, and elEconomista, the world’s leading economic newspaper in Spanish. The companies that obtain the certificate have had to pass a process developed and audited by INFORMA on the main indicators that determine excellence in business management.

In 2020, 1,300 companies have opted for the CIEGE Seal in its third edition. INMUNOTEK is among the 47 that have obtained the certificate this year and among the 24 that have managed to revalidate it.

+info


La entrada CIEGE Seal for INMUNOTEK at Business Excellence se publicó primero en Inmunotek.


Source: Inmunotek News

MV130 (Bactek) on mesenchymal stem cells

{$excerpt:n}

.

11/2020. MV130 (Bactek) and mesenchymal stem cells

Frontiers in Immunology publishes an interesting study on the effect of MV130 (Bactek) on mesenchymal stem cells.   

MV130 (Bactek) is a sublingual preparation composed of inactivated bacteria selected by INMUNOTEK and designed to prevent recurrent respiratory infections. This study analyzes the uptake of MV130 bacteria by mesenchymal stem cells from the oral mucosa in mice and the effect of these bacteria on the function of human mesenchymal stem cells. 

The results of this research indicate that mesenchymal stem cells are very effective in capturing these bacteria, where they are stored as a reservoir, to later transfer them to the (dendritic) cells responsible for initiating an immune response. In addition, the functionality of the mesenchymal stem cells is modified towards an initial pro-inflammatory activity and an anti-inflammatory activity in a second stage. 

This research has been carried out under the co-direction of Prof. Ángeles Vicente and Dr. Jaris Valencia of the Department of Cell Biology, Faculty of Medicine, Complutense University of Madrid, with the collaboration of INMUNOTEK.

La entrada MV130 (Bactek) on mesenchymal stem cells se publicó primero en Inmunotek.


Source: Inmunotek News

MV130 (Bactek) and mesenchymal stem cells

{$excerpt:n}

.

11/2020. MV130 (Bactek) y células madre mesenquimales

Frontiers in Immunology publishes an interesting study on the effect of MV130 (Bactek) on mesenchymal stem cells.   

MV130 (Bactek) is a sublingual preparation composed of inactivated bacteria selected by INMUNOTEK and designed to prevent recurrent respiratory infections. This study analyzes the uptake of MV130 bacteria by mesenchymal stem cells from the oral mucosa in mice and the effect of these bacteria on the function of human mesenchymal stem cells. 

The results of this research indicate that mesenchymal stem cells are very effective in capturing these bacteria, where they are stored as a reservoir, to later transfer them to the (dendritic) cells responsible for initiating an immune response. In addition, the functionality of the mesenchymal stem cells is modified towards an initial pro-inflammatory activity and an anti-inflammatory activity in a second stage. 

This research has been carried out under the co-direction of Prof. Ángeles Vicente and Dr. Jaris Valencia of the Department of Cell Biology, Faculty of Medicine, Complutense University of Madrid, with the collaboration of INMUNOTEK.

La entrada MV130 (Bactek) and mesenchymal stem cells se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK HELLAS new subsidiary

{$excerpt:n}

11/2020. INMUNOTEK opens new subsidiary in Greece

The Spanish pharmaceutical company expands further in Europe with a new subsidiary office based in Athens. 

Madrid, November 1st 2020 – Inmunotek, a Spanish pharmaceutical company that researches, develops and manufactures products in the allergy and immunotherapy field, announces the expansion of its European network with the opening of a new subsidiary in Athens, Greece: Inmunotek Hellas.

After successfully establishing other subsidiaries along with many cooperation partners around the world, the new branch consolidates Inmunotek’s Group operations in Greece, which was previously managed through the distributor Arma Pharma, as a response to the increasing demand of its innovative portfolio of pharmaceutical products.

“Greece is one of our most important markets. We are excited to announce the creation of Inmunotek Hellas to further strengthen our European presence and to fulfil our commitment with the Greek community to delivering innovative immunotherapy”, said José-Luis Subiza MD PhD, President-CEO of Inmunotek.

The new opening of Inmunotek Hellas will also see the launch of a new, next-generation vaccine targeting dendritic cells based on mannan-allergoid conjugates, for the treatment of inhalant allergy. Greece is going to be one of the first countries in the world to introduce this novel type of allergen-specific immunotherapy.

“The establishment of this new subsidiary matches the trust and loyalty of the Greek Healthcare Professionals with the scientifically-driven and innovative products of the International Inmunotek Group”, stated Christos Ntais MD PhD, Medical Director of Inmunotek Hellas.

About Inmunotek

Inmunotek is a Spanish pharmaceutical manufacturing company with more than 25 years experience in the Immunology field for the diagnosis and treatment of allergic and other immune-based diseases in human and veterinary medicine.

Currently, Inmunotek is present in more than 50 countries in all continents, with subsidiaries in Portugal, Mexico, Perú, Colombia, and now in Greece. As a leading company in business growth and innovation, Inmunotek has been recognised for its contributions in the medical field with the “National Innovation Award 2019” by the Spanish Ministry of Science and Innovation, “Best SME of the Year 2019” by CEPYME. It has also been listed in the main rankings of fastest-growing companies in Europe (FT1000, Inc5000, CEPYME500), amongst other acknowledgements.


La entrada INMUNOTEK HELLAS new subsidiary se publicó primero en Inmunotek.


Source: Inmunotek News

Occupational allergy to peach tree pollen

{$excerpt:n}

.

10/2020. Occupational allergy to peach tree pollen

A study published in the journal Occupational and Environmental Medicine conducted on workers exposed to peach tree pollen demonstrates sensitization to this pollen and its allergen Pru p 9.  

In this field study, carried out on workers who perform their job in the flowering season of peach trees, a clinical sensitization to their pollen is evidenced with the appearance of rhinitis and asthma symptoms. The main pollen allergen causing sensitization is Pru p 9, recently identified by the research group. The results are of interest, since the peach blossom is of entomophilic pollination (through insects) and its pollen is considered difficult to release into the air. For this reason, a new cause of occupational rhinitis & asthma is identified and this possibility is opened to other fruit trees with similar characteristics.

This research has been carried out in the region of Murcia (Spain) under the direction of Dr. Miguel Blanca, from the Allergy Department of the Infanta Leonor Hospital (Madrid), with the participation of the Morales Meseguer and Virgen de Arrixaca hospitals (Murcia), the Department of Biochemistry and Molecular Biology, from the Faculty of Chemistry of the Complutense University of Madrid and INMUNOTEK.

La entrada Occupational allergy to peach tree pollen se publicó primero en Inmunotek.


Source: Inmunotek News

INMUNOTEK Top-10 according to Pharma Tech Outlook

{$excerpt:n}

10/2020. INMUNOTEK featured by Pharma Tech Outlook

INMUNOTEK is the cover of  Pharma Tech Outlook, a magazine specialized in pharmaceutical technology, after being recognized among the main European providers of immunotherapies. 

According to the magazine, immunotherapy, which is applied to autoimmune and infectious diseases, cancer or allergies, represents one of the best examples of personalized medicine. The immunotherapy sector is very dynamic and in continuous evolution.

Pharma Tech Outlook has included INMUNOTEK among the top-10 European immunotherapy providers that stand out for their technological and innovative strategies, and has highlighted it on the cover of this special issue.

 +info


La entrada INMUNOTEK Top-10 according to Pharma Tech Outlook se publicó primero en Inmunotek.


Source: Inmunotek News